Risk of relapse after meningococcal C conjugate vaccine in nephrotic syndrome

A. S. Abeyagunawardena; D. Goldblatt; Nicholas Andrews; R. S. Trompeter

doi:10.1016/S0140-6736(03)14072-X

Risk of relapse after meningococcal C conjugate vaccine in nephrotic syndrome

A. S. Abeyagunawardena, D. Goldblatt, Nicholas Andrews, R. S. Trompeter^*

^*Corresponding author for this work

C-19: HP: Pillar Testing Staff budget centre

Research output: Contribution to journal › Article › peer-review

47 Citations (Scopus)

Abstract

In November, 1999, all children under age 18 years in the UK were offered immunisation with the newly introduced meningococcal C conjugate vaccine (MCCV). In a cohort of 106 patients with nephrotic syndrome, there were 63 relapses during the 12 months before vaccination, and 96 during the equivalent period postvaccination (p=0.009). The relapse rate of nephrotic syndrome increased significantly after administration of MCCV. Whether to vaccinate such children needs to be carefully considered.

Original language	English
Pages (from-to)	449-450
Number of pages	2
Journal	The Lancet
Volume	362
Issue number	9382
DOIs	https://doi.org/10.1016/S0140-6736(03)14072-X
Publication status	Published - 9 Aug 2003

Bibliographical note

Funding Information:
ASA was supported by The Caring for Kids Fund (Child Health Research Appeal Trust). The sponsors of the study had no role in study design, data collection, data analysis, data interpretation, or in writing of the report.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/S0140-6736(03)14072-X

Cite this

@article{4803a68b342f48daa3fa9aebe2827bf9,

title = "Risk of relapse after meningococcal C conjugate vaccine in nephrotic syndrome",

abstract = "In November, 1999, all children under age 18 years in the UK were offered immunisation with the newly introduced meningococcal C conjugate vaccine (MCCV). In a cohort of 106 patients with nephrotic syndrome, there were 63 relapses during the 12 months before vaccination, and 96 during the equivalent period postvaccination (p=0.009). The relapse rate of nephrotic syndrome increased significantly after administration of MCCV. Whether to vaccinate such children needs to be carefully considered.",

author = "Abeyagunawardena, {A. S.} and D. Goldblatt and Nicholas Andrews and Trompeter, {R. S.}",

note = "Funding Information: ASA was supported by The Caring for Kids Fund (Child Health Research Appeal Trust). The sponsors of the study had no role in study design, data collection, data analysis, data interpretation, or in writing of the report.",

year = "2003",

month = aug,

day = "9",

doi = "10.1016/S0140-6736(03)14072-X",

language = "English",

volume = "362",

pages = "449--450",

journal = "The Lancet",

issn = "0140-6736",

publisher = "Elsevier",

number = "9382",

}

TY - JOUR

T1 - Risk of relapse after meningococcal C conjugate vaccine in nephrotic syndrome

AU - Abeyagunawardena, A. S.

AU - Goldblatt, D.

AU - Andrews, Nicholas

AU - Trompeter, R. S.

N1 - Funding Information: ASA was supported by The Caring for Kids Fund (Child Health Research Appeal Trust). The sponsors of the study had no role in study design, data collection, data analysis, data interpretation, or in writing of the report.

PY - 2003/8/9

Y1 - 2003/8/9

N2 - In November, 1999, all children under age 18 years in the UK were offered immunisation with the newly introduced meningococcal C conjugate vaccine (MCCV). In a cohort of 106 patients with nephrotic syndrome, there were 63 relapses during the 12 months before vaccination, and 96 during the equivalent period postvaccination (p=0.009). The relapse rate of nephrotic syndrome increased significantly after administration of MCCV. Whether to vaccinate such children needs to be carefully considered.

AB - In November, 1999, all children under age 18 years in the UK were offered immunisation with the newly introduced meningococcal C conjugate vaccine (MCCV). In a cohort of 106 patients with nephrotic syndrome, there were 63 relapses during the 12 months before vaccination, and 96 during the equivalent period postvaccination (p=0.009). The relapse rate of nephrotic syndrome increased significantly after administration of MCCV. Whether to vaccinate such children needs to be carefully considered.

UR - http://www.scopus.com/inward/record.url?scp=0042736671&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(03)14072-X

DO - 10.1016/S0140-6736(03)14072-X

M3 - Article

C2 - 12927434

AN - SCOPUS:0042736671

VL - 362

SP - 449

EP - 450

JO - The Lancet

JF - The Lancet

SN - 0140-6736

IS - 9382

ER -

Risk of relapse after meningococcal C conjugate vaccine in nephrotic syndrome

Abstract

Bibliographical note

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this